GlaxoSmithKline is making its largest oncology acquisition in years with a $10.6 billion deal for US-based cancer drug developer Nuvalent, betting that a trio of promising lung cancer therapies can help drive future growth and offset looming patent expirations in its HIV portfolio.
The acquisition, announced on Tuesday, will give the British pharmaceutical giant access to three experimental lung cancer treatments, including two candidates currently under review by the US Food and Drug Administration and expected to receive regulatory decisions later this year.
While the deal strengthens GSK’s long-term ambitions in oncology, investors appeared unconvinced by the scale and price of the transaction.
GSK shares fell around 3% in early trading, making the stock one of the weakest performers on the FTSE 100, while Nuvalent shares surged nearly 38% in premarket trading in the United States.
Premium offer for promising cancer assets
Under the terms of the agreement, GSK will launch a cash tender offer of $124 per share for Nasdaq-listed Nuvalent, representing a roughly 40% premium to the company’s closing price on Monday.
Although the headline value of the transaction is $10.6 billion, GSK said its net investment would be approximately $9.4 billion after accounting for cash held on Nuvalent’s balance sheet.
The acquisition provides GSK with access to two late-stage lung cancer drug candidates and a third earlier-stage asset, giving the company multiple opportunities in one of the pharmaceutical industry’s most lucrative treatment areas.
GSK expects the deal to contribute to revenue growth and strengthen core operating profit from next year.
The company also said the acquisition would help cushion the impact of patent expirations for dolutegravir, a key HIV treatment, between 2028 and 2030.
The transaction remains incremental to GSK’s broader target of generating more than £40 billion ($53.4 billion) in annual sales by 2031.
Oncology remains central to growth strategy
The acquisition marks another step in GSK’s effort to rebuild its oncology business after exiting the sector more than a decade ago.
In 2015, GSK completed a major asset swap with Swiss pharmaceutical company Novartis, selling its oncology division in exchange for Novartis’ vaccines business.
The companies also merged their consumer healthcare operations, with GSK later buying out Novartis’ stake for $13 billion.
Since then, GSK has steadily rebuilt its cancer portfolio through acquisitions and licensing agreements.
Previous deals have included purchases of oncology-focused companies such as Tesaro, Sierra Oncology, and IDRx.
Chief Executive Luke Miels described the company’s approach as a gradual rebuilding process.
“Our strategy has been a brick-by-brick building approach,” Miels told reporters.
Unlike many of GSK’s recent acquisitions, which focused on single-product companies, the Nuvalent deal brings multiple assets under one transaction.
Miels said the acquisition remains consistent with GSK’s strategy of targeting companies with validated science that address shortcomings in existing treatments.
Investors question size and timing
Despite the strategic rationale, analysts said the market reaction reflected concerns over the scale of the investment and the risks attached to Nuvalent’s pipeline.
Russ Mould, investment director at AJ Bell, said investors appear wary of the size of the acquisition and the premium GSK is paying.
“GSK is paying a hefty premium to get the deal over the line, and the two big lung cancer products flagged by Luke Miels still await regulatory approval,” Mould said.
“In rolling the dice on such a big transaction, he is undoubtedly taking a risk.”
Victoria Scholar, head of investment at Interactive Investor, echoed those concerns, noting that the deal is significantly larger than most of GSK’s previous acquisitions.
“GSK shares are down around 3% today, reflecting the fact that this is a mammoth deal even by GSK’s standards,” Scholar said.
She noted that the acquisition dwarfs previous oncology deals such as Tesaro and Sierra Oncology and carries execution risks given the reliance on regulatory approvals and future commercial success.
Growth potential outweighs near-term concerns
Despite investor caution, analysts acknowledged that GSK is securing a substantial oncology pipeline through a single transaction.
The company believes the acquisition will begin contributing to sales growth and earnings expansion from next year without disrupting its dividend policy.
Miels said GSK would need time to integrate Nuvalent but stressed that the company would retain the financial flexibility to pursue additional opportunities if attractive assets emerge.
The post GSK’s $10.6B Nuvalent takeover fails to impress investors as shares fall: here's why appeared first on Invezz